Seattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital
October 26, 2018 7:35 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $92.00 (from $98.00) while maintaining a Outperform rating.
The analyst notes the surprise Adcetris miss brings questions to 1L HL aspect of bull thesis.
... More